Zimmer Biomet Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan.
It is a $17.0B healthcare company. Revenue grew 8.6% over the last year, it keeps 9¢ of every dollar of sales as profit, and its net debt equals ~4.2 years of free cash flow. It trades at 21.5× earnings — near the lowest of its own history.
- Website
- zimmerbiomet.com
- Location
- Warsaw, IN
- Employees
- 17 000
- Sector
- Healthcare
- Founded
- 1927
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong valuation and quality; Profitability lags behind.
Valuation90
- P/E vs own history4th pct · 25/25
- FCF yield9.0% · 25/25
- P/S2.0x · 20/25
- EV/EBITDA13.0x · 20/25
Growth51
- Revenue CAGR1.2% · 6/25
- Net income CAGR15.1% · 20/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growth104.3% · 25/25
Profitability35
- ROIC3.7% · 5/25
- ROE6.3% · 5/25
- Net margin9.5% · 13/25
- Operating margin14.2% · 12/25
Health58
- Altman Z2.15 · 18/25
- Current ratio1.69 · 18/25
- Interest coverage3.8x · 10/25
- Net cash / debtD/A 27% · 12/25
Quality77
- Piotroski F6/9 · 15/25
- Beneish M-2.66 · 25/25
- FCF conversion189% · 25/25
- Margin stabilityσ 9.4% · 12/25
Moat55
- ROIC >12% years0/10 yrs · 0/25
- Median gross margin71.1% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst -4.8% · 5/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2026AcquisitionZimmer Biomet acquired the iovera pain therapy business from Pacira BioSciences Inc
- Oct 7, 2025AcquisitionZimmer Biomet completed its acquisition of Monogram Technologies Inc
- 2024ProductZimmer introduced the ROSA Shoulder, said to be the world's first robotic surgery system for shoulder…
- 2023AcquisitionThe company announced its intention to acquire Embody, Inc
- FY2017FinancialBest year on record$1.81B net income
- FY2016FinancialFirst recorded profitable year$306M net income
- FY2016FinancialRevenue already above $1B$7.68B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- Jun 29, 2015AcquisitionThe company changed the ticker symbol to "ZBH" to reflect its acquisition of Biomet
- Jun 24, 2015AcquisitionEuropean Commission (“EC”) conditionally cleared Zimmer's proposed acquisition of Biomet, Inc
- 2012AcquisitionThe company acquired Reno, Nevada-based Synvasive Technology, Inc
- 2011AcquisitionThe company acquired ExtraOrtho, Inc. (ExtraOrtho)
- 2001MilestoneZimmer was spun off from Bristol Myers Squibb and began trading on the New York Stock Exchange, on August…
- 1927FoundedIt was founded in 1927 to produce aluminum splints
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (69.9%)
- Strong cash conversion — FCF is 17.9% of revenue
Watch-outs
- Loss-making in 2 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+8.6% YoY
- Profitable — makes more than it spends$807M TTM
- Profit growing — earnings are higher than last year+47.8% YoY
- Generates cash — cash left after running and investing$1.52B TTM
- Debt under control — could handle its obligations~4.2y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$17.0B market cap
- Not printing shares — share count not ballooning — you keep your slice-4.0% shares over ~5y
- Proven track record — years of profitability behind it8/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 2.2 — grey
- Pays a dividend — returns cash to shareholdersyield 1.09%
- Valuation not extreme — price not wildly above earningsP/E 21.5
Peer comparisonZimmer Biomet Holdings, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| ZBH this company | $17.0B | 21.5 | +8.6% | 9.5% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: ZBH vs LLY · ZBH vs JNJ · ZBH vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/ZBH
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of ZBH on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $89.00 · market cap $17.0B.